A Double-Blind, Controlled Phase 2 Study of the Safety and Efficacy of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Traumatic Brain Injury (TBI)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 07 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

12 Feb 2025 According to a SanBio media release, the interim analysis results published in the online edition of Neurotrauma Reports
12 Feb 2025 The interim analysis results published in the SanBio media release
31 Jul 2024 According to a SanBio media release, company obtained conditional and time-limited marketing approval for the human somatic stem cell-processed product AKUUGO suspension for intracranial implantation in Japan, for the indication of improving chronic motor paralysis resulting from traumatic brain injury based on results this trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com